Kümmel, Sherko

Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 3,270

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 2,157

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 922

Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis.

Haller, H., Winkler, M. M., Klose, P., Dobos, G., Kümmel, S., & Cramer, H. (2017) · Acta Oncologica

Mindfulness and Compassion InterventionsCancer survivorship and care

Cited by 277

Yoga and meditation for menopausal symptoms in breast cancer survivors—a randomized controlled trial

Cramer, H., Rabsilber, S., Lauche, R., Kümmel, S., & Dobos, G. (2015) · Cancer

Cancer survivorship and careMenopause: Health Impacts and Treatments

Cited by 131

Hypnosis in Breast Cancer Care: A Systematic Review of Randomized Controlled Trials

Cramer, H., Lauche, R., Paul, A., Langhorst, J., Kümmel, S., & Dobos, G. J. (2015) · Integrative Cancer Therapies

Pain Management and Placebo EffectCancer survivorship and care

Cited by 111

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 72

Integrating mindfulness in supportive cancer care: a cohort study on a mindfulness-based day care clinic for cancer survivors

Dobos, G., Overhamm, T., Büssing, A., Ostermann, T., Langhorst, J., Kümmel, S., Paul, A., & Cramer, H. (2015) · Supportive Care in Cancer

Cancer survivorship and careMindfulness and Compassion Interventions

Cited by 54

Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib

Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S., Chow, L., Sohn, J., Lee, K. S., et al. (2021) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 30